Search Within

David P Kelsen

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (30)
  2. Meeting Abstract (27)
  3. Editorial (1)
Groups
  1. Center for Pancreatic Cancer Research (58)
  2. Department of Medicine (58)
  3. GSK Faculty (58)
  4. Gastrointestinal Oncology Service (58)
  5. Human Oncology and Pathogenesis Program (58)
  6. Solid Tumor Oncology Division (58)

More Groups

People
  1. Marinela Capanu (30)
  2. Nikolaus Schultz (28)
  3. Geoffrey Ku (25)
  4. Joanne Chou (25)
  5. Yelena Janjigian (25)
  6. Michael Berger (23)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (4)
  4. 2022 (4)
  5. 2021 (5)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (22)
  2. Clinical Cancer Research (6)
  3. Annals of Oncology (4)
  4. Cancer (2)
  5. Cancer Discovery (2)
  6. Cancer Research (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (22)
  2. American Association for Cancer Research (10)
  3. Oxford University Press (7)
  4. Nature Publishing Group (5)
  5. Wiley Blackwell (3)
  6. Cell Press (2)

More Publishers

Results (58)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy
    Meeting Abstract

    Greally, M.; Walch, H. S.; Chou, J. F.; Capanu, M.; Kelsen, D. P.; Ilson, D. H.; Janjigian, Y. Y.; Schultz, N.; Ku, G. Y.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Pilot study of plasma KRAS as a prognostic biomarker in localized pancreas ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Krantz, B. A.; Gedvilaite, E.; Chou, J. F.; Capanu, M.; You, D.; Yu, K. H.; Varghese, A. M.; Iacobuzio-Donahue, C. A.; Kelsen, D. P.; Tsui, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer
    Journal Article

    Greally, M.; Chou, J. F.; Chatila, W. K.; Margolis, M.; Capanu, M.; Hechtman, J. F.; Tuvy, Y.; Kundra, R.; Daian, F.; Ladanyi, M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer
    Journal Article

    Won, E.; Basunia, A.; Chatila, W. K.; Hechtman, J. F.; Chou, J. F.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
    Journal Article

    Mondaca, S.; Margolis, M.; Sanchez-Vega, F.; Jonsson, P.; Riches, J. C.; Ku, G. Y.; Hechtman, J. F.; Tuvy, Y.; Berger, M. F.; Shah, M. A.; more...
    Gastric Cancer (2019)

    Fulltext@MSK | Save
  • EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer
    Journal Article

    Sanchez-Vega, F.; Hechtman, J. F.; Castel, P.; Ku, G. Y.; Tuvy, Y.; Won, H.; Fong, C. J.; Bouvier, N.; Nanjangud, G. J.; Soong, J.; more...
    Cancer Discovery (2019)

    Fulltext@MSK | Save
  • Detection of germline homologous recombination deficiency (HRD) in patients with metastatic esophagogastric (EG) cancer using clinical next generation sequencing (NGS)
    Meeting Abstract

    Janjigian, Y. Y.; Jonsson, P.; Kemel, Y.; Joseph, V.; Tuvy, Y.; Shameer, Z.; Ravichandran, V.; Zhang, L. Y.; Mandelker, D.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tumor mutation burden (TMB) and immune- related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC)
    Meeting Abstract

    Greally, M.; Chatila, W. K.; Margolis, M.; Hechtman, J. F.; Tuvy, Y.; Kundra, R.; Ladanyi, M.; Kelsen, D. P.; Ilson, D. H.; Berger, M. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Krantz, B. A.; Tsui, D.; Lowery, M. A.; Capanu, M.; Yu, K. H.; Kelsen, D. P.; Gedvilaite, E.; Zhang, L.; Selcuklu, S. D.; You, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save